Teva’s chief drug Austedo—approved in Huntington’s disease and tardive dyskinesia—grew sales 19% to $498 million for the ...

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.

Teva Pharmaceuticals swung to a second-quarter profit though narrowed its full-year adjusted earnings guidance. The Israeli based pharmaceutical company posted a second-quarter profit of $282 million, ...

The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help ...

Parsippany: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced that the U.S. Food ...

FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children ...

This FTSE 100 stock could be on the verge of stealing enormous chunks of market share from some of the largest pharmaceutical ...

The expiration of Viatris’s EpiPen patent in September 2025 will likely result in increased competition and lower costs in ...

The FDA expanded the indication for fremanezumab (Ajovy) injection for episodic migraine prevention to include children and ...

In Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., Appeal No. 25-1228, The Federal Circuit found that claims reciting a ...

In recent health news, WuXi Apptec plans a $980 million share expansion, nursing strikes erupt in Nigeria, Teva ...

Teva's Ajovy gains FDA approval for pediatric migraine prevention, offering hope for children aged 6-17 with this debilitating condition.